{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:35:33Z","timestamp":1761129333956,"version":"3.37.3"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["K23AI102639","R21AI104441"],"award-info":[{"award-number":["K23AI102639","R21AI104441"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12879-016-1576-1","type":"journal-article","created":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T09:42:48Z","timestamp":1464774168000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Urine colorimetry to detect Low rifampin exposure during tuberculosis therapy: a proof-of-concept study"],"prefix":"10.1186","volume":"16","author":[{"given":"Isaac","family":"Zentner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans P.","family":"Schlecht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorna","family":"Khensouvann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neo","family":"Tamuhla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Kutzler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijay","family":"Ivaturi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jotam G.","family":"Pasipanodya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tawanda","family":"Gumbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles A.","family":"Peloquin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory P.","family":"Bisson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Vinnard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,6,1]]},"reference":[{"key":"1576_CR1","unstructured":"Treatment of tuberculosis. MMWR Recomm Rep 2003;52:1\u201377."},{"key":"1576_CR2","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1128\/AAC.00749-10","volume":"55","author":"J Pasipanodya","year":"2011","unstructured":"Pasipanodya J, Gumbo T. An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future. Antimicrob Agent Chemother. 2011;55:24\u201334.","journal-title":"Antimicrob Agent Chemother"},{"key":"1576_CR3","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1093\/infdis\/jit352","volume":"208","author":"JG Pasipanodya","year":"2014","unstructured":"Pasipanodya JG, McIlleron H, Burger A, Wash PA, Smith P, Gumbo T. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis. 2014;208:1464\u201373.","journal-title":"J Infect Dis"},{"key":"1576_CR4","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1086\/431984","volume":"41","author":"JW Tappero","year":"2005","unstructured":"Tappero JW, Bradford WZ, Agerton TB, Hopewell P, Reingold AL, Lockman S, et al. Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana. Clin Infect Dis. 2005;41:461\u20139.","journal-title":"Clin Infect Dis"},{"key":"1576_CR5","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1164\/rccm.201410-1843OC","volume":"191","author":"SE Dorman","year":"2015","unstructured":"Dorman SE, Savic RM, Goldberg S, et al. Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial. Am J Respir Crit Care Med. 2015;191:333\u201343.","journal-title":"Am J Respir Crit Care Med"},{"key":"1576_CR6","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1093\/cid\/cis353","volume":"55","author":"JG Pasipanodya","year":"2012","unstructured":"Pasipanodya JG, Sristava S, Gumbo T. Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy. Clin Infect Dis. 2012;55:169\u201377.","journal-title":"Clin Infect Dis"},{"key":"1576_CR7","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1128\/AAC.03931-14","volume":"59","author":"E Chigutsa","year":"2015","unstructured":"Chigutsa E, Pasipanodya JG, Visser ME, van Helden PD, Smith PJ, Sirgel FA, et al. Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis. Antimicrob Agents Chemother. 2015;59:38\u201345.","journal-title":"Antimicrob Agents Chemother"},{"key":"1576_CR8","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s40265-014-0222-8","volume":"74","author":"A Alsultan","year":"2014","unstructured":"Alsultan A, Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs. 2014;74:839\u201354.","journal-title":"Drugs"},{"key":"1576_CR9","doi-asserted-by":"publisher","first-page":"78","DOI":"10.4046\/trd.2015.78.2.78","volume":"78","author":"SK Heysell","year":"2015","unstructured":"Heysell SK, Moore JL, Peloquin CA, Ashkin D, Houpt ER. Outcomes and use of therapeutic drug monitoring in multidrug-resistant tuberculosis patients treated in Virginia, 2009\u20132014. Tuberc Respir Dis. 2015;78:78\u201384.","journal-title":"Tuberc Respir Dis"},{"key":"1576_CR10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.talanta.2013.12.043","volume":"121","author":"DH Vu","year":"2014","unstructured":"Vu DH, Koster RA, Bolhuis MS, Greijdanus B, Altena RV, Nguyen DH, et al. Simultaneous determination of rifampicin, clarithromycin and their metabolites in dried blood spots using LC-MS\/MS. Talanta. 2014;121:9\u201317.","journal-title":"Talanta"},{"key":"1576_CR11","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.jpba.2007.04.007","volume":"44","author":"AL Allanson","year":"2007","unstructured":"Allanson AL, Cotton MM, Tettey JN, Boyter AC. Therapeutic drug monitoring by dried blood spot: progress to date and future directions. J Pharm Biomed Anal. 2007;44:963\u20139.","journal-title":"J Pharm Biomed Anal"},{"key":"1576_CR12","first-page":"480","volume":"28","author":"S Brechnuhler","year":"1978","unstructured":"Brechnuhler S, Fluehler H, Riess W, Theobald W. The renal elimination of rifampin as a function of the oral dose. A convenient way to assess relative bioavailability. Arzneimittelforschung. 1978;28:480\u20133.","journal-title":"Arzneimittelforschung"},{"issue":"Suppl 3","key":"1576_CR13","first-page":"S301","volume":"11","author":"GA Ellard","year":"1999","unstructured":"Ellard GA, Fourie PB. Rifampin bioavailability: a review of its pharmacology and the chemotherapeutic necessity for ensuring optimal absorption. Int J Tuberc Lung Dis. 1999;11 Suppl 3:S301\u20138.","journal-title":"Int J Tuberc Lung Dis"},{"key":"1576_CR14","first-page":"691","volume":"5","author":"G Pillai","year":"2001","unstructured":"Pillai G, Ellard GA, Smith PJ, Fourie PB. The potential use of urinary excretion data for assessing the relative bioavailability of rifampin in fixed dose combination anti-tuberculosis formulations. Int J Tuberc Lung Dis. 2001;5:691\u20135.","journal-title":"Int J Tuberc Lung Dis"},{"key":"1576_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0045913","volume":"7","author":"I Nicolau","year":"2012","unstructured":"Nicolau I, Tian L, Menzies D, Ostiguy G, Pai M. Point-of-care urine tests for smoking status and isoniazid treatment monitoring in adult patients. PLoS One. 2012;7, e45913.","journal-title":"PLoS One"},{"key":"1576_CR16","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1378\/chest.61.6_Supplement.526","volume":"61","author":"S Sunahara","year":"1972","unstructured":"Sunahara S, Nakagawa H. Metabolic study and controlled clinical trials of rifampin. Chest. 1972;61:526\u201332.","journal-title":"Chest"},{"key":"1576_CR17","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198509844.001.0001","volume-title":"The statistical evaluation of medical tests for classification and prediction","author":"MS Pepe","year":"2003","unstructured":"Pepe MS. The statistical evaluation of medical tests for classification and prediction. New York: Oxford University Press; 2003."},{"key":"1576_CR18","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1002\/(SICI)1097-0258(20000515)19:9<1141::AID-SIM479>3.0.CO;2-F","volume":"19","author":"J Carpenter","year":"2000","unstructured":"Carpenter J, Bithell J. Bootstrap confidence intervals: when, which, what? a practical guide for medical statisticians. Stat Med. 2000;19:1141\u201364.","journal-title":"Stat Med"},{"key":"1576_CR19","doi-asserted-by":"publisher","unstructured":"Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics. 2011. doi: 10.1186\/1471-2105-12-77 .","DOI":"10.1186\/1471-2105-12-77"},{"key":"1576_CR20","doi-asserted-by":"publisher","first-page":"3781","DOI":"10.1128\/AAC.01533-06","volume":"51","author":"T Gumbo","year":"2007","unstructured":"Gumbo T et al. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob Agents Chemother. 2007;51:3781\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"1576_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.164","author":"HS Schaaf","year":"2015","unstructured":"Schaaf HS, Garcia-Prats AJ, Donald PR. Antituberculosis drugs in children. Clin Pharmacol Ther. 2015. doi: 10.1002\/cpt.164 .","journal-title":"Clin Pharmacol Ther"},{"key":"1576_CR22","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/1471-2334-5-111","volume":"5","author":"MR van Cleeff","year":"2005","unstructured":"van Cleeff MR, Kivihya-Ndugga LE, Meme H, Odhiambo JA, Klatser PR. The role and performance of chest X-ray for the diagnosis of tuberculosis: a cost-effectiveness analysis in Nairobi. Kenya BMC Infect Dis. 2005;5:111.","journal-title":"Kenya BMC Infect Dis"},{"key":"1576_CR23","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/1471-2334-9-53","volume":"9","author":"A Cattamanchi","year":"2009","unstructured":"Cattamanchi A, Dowdy DW, Davis JL, Worodria W, Yoo S, Joloba M, et al. Sensitivity of direct versus concentrated sputum smear microscopy in HIV-infected patients suspected of having pulmonary tuberculosis. BMC Infect Dis. 2009;9:53. doi: 10.1186\/1471-2334-9-53 .","journal-title":"BMC Infect Dis"},{"key":"1576_CR24","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.3109\/03639045.2013.819880","volume":"40","author":"JW Chae","year":"2014","unstructured":"Chae JW, Seo JW, Mahat BM, Yun HY, Baek IH, Lee BY, et al. A simple pharmacokinetic model of alendronate developed using plasma concentration and urine excretion data from healthy men. Drug Dev Ind Pharm. 2014;40:1325\u20139.","journal-title":"Drug Dev Ind Pharm"},{"key":"1576_CR25","doi-asserted-by":"publisher","first-page":"4192","DOI":"10.1128\/AAC.00353-10","volume":"54","author":"M Weiner","year":"2010","unstructured":"Weiner M, Peloquin C, Burman W, Luo CC, Engle M, Prihoda TJ, et al. Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations. Antimicrob Agents Chemother. 2010;54:4192\u2013200.","journal-title":"Antimicrob Agents Chemother"},{"key":"1576_CR26","doi-asserted-by":"publisher","first-page":"291294","DOI":"10.1155\/2012\/291294","volume":"2012","author":"W Thanassi","year":"2012","unstructured":"Thanassi W, Noda A, Hernandez B, et al. Delineating a retesting zone using receiver operating characteristic analysis on serial QuantiFERON tuberculosis test results in US healthcare workers. Pulm Med. 2012;2012:291294.","journal-title":"Pulm Med"},{"key":"1576_CR27","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1164\/rccm.201407-1264OC","volume":"191","author":"MJ Boeree","year":"2015","unstructured":"Boeree MJ, Diacon AH, Dawson R, Newell J, Terpeluk P, Marder D, et al. A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis. Am J Respir Crit Care Med. 2015;191:1058\u201365.","journal-title":"Am J Respir Crit Care Med"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-016-1576-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-016-1576-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-016-1576-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-016-1576-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T07:58:13Z","timestamp":1718611093000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-016-1576-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["1576"],"URL":"https:\/\/doi.org\/10.1186\/s12879-016-1576-1","relation":{},"ISSN":["1471-2334"],"issn-type":[{"type":"electronic","value":"1471-2334"}],"subject":[],"published":{"date-parts":[[2016,6,1]]},"assertion":[{"value":"13 November 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"242"}}